| Question 1: Conivaptan (YM 087, brand name Vaprisol) is a non-peptide inhibitor of ________ (vasopressin). |
| Question 2: Effectively, it causes iatrogenic nephrogenic ________. |
| Question 3: It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH), and there is some evidence it may be effective in ________. |